| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of formula (I) or their pharmaceutically acceptable salt, which are neutrophil elastase (hNE) inhibitors. The compounds can be applicable for treating a disease or condition, which involves hNE, or in producing a medicinal agent. This disease or condition can be presented by chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, emphysema caused by smoking, or mucoviscidosis, asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, nonspecific ulcerative colitis or irritable bowel disease. In formula (I),A represents C-R; Rand Rrepresent hydrogen; Rrepresents hydrogen; Rand Rare independently specified in hydrogen and C-C-alkyl, which can be additionally substituted by halogen; Rrepresents -COR; -X-X- represents -NR-CO-; Rrepresents a radical of formula -[Alk]-[Alk]-Z, wherein p and q independently mean 0 or 1 provided, p and q does not mean 0 at the same time; each Alkand Alkindependently represent C-C-alkylene radical; Z represents (1) -N(R)(R), wherein Rand Rindependently represent hydrogen or C-C-alkyl group; or (2) -N(R)(R)(R), wherein R, Rand Rindependently represent C-C-alkyl group; Ris specified in hydrogen and (C-C)alkyl; optionally in the form of a pharmaceutically acceptable salt.EFFECT: compounds can be applicable for treating a disease or condition, which involves hNE, or in producing a medicinal agent.14 cl, 3 ex |
